Skip to main content

Table 2 Longitudinal analysis of allergic disease symptoms with sensitization at 1, 3 and 6 years of age

From: Prenatal omega-3 LCPUFA and symptoms of allergic disease and sensitization throughout early childhood – a longitudinal analysis of long-term follow-up of a randomized controlled trial

Outcome

Year

ω-3 LCPUFAa

n (%)

Controla

n (%)

RR (95% CI)

P-value

Interaction

p-value

Adjusted RRb

(95% CI)

Adjusted

p-value

Interaction p-valueb

Any allergic disease symptoms with sensitization

1

15/363 (4.13%)

22/330 (6.67%)

0.62 (0.33, 1.17)

0.14

0.51

0.63 (0.33, 1.19)

0.16

0.49

3

58/313 (18.53%)

61/291 (20.96%)

0.88 (0.64, 1.22)

0.45

 

0.89 (0.65, 1.23)

0.48

 

6

76/280 (27.14%)

82/263 (31.18%)

0.87 (0.67, 1.13)

0.30

 

0.92 (0.71, 1.19)

0.54

 

All years

  

0.85 (0.66, 1.08)

0.18

 

0.88 (0.69, 1.12)

0.29

 

Rhinitis symptoms with sensitization

3

25/327 (7.65%)

28/301 (9.30%)

0.82 (0.49, 1.38)

0.46

0.90

0.83 (0.50, 1.39)

0.48

0.87

6

55/298 (18.46%)

60/276 (21.74%)

0.85 (0.61, 1.18)

0.33

 

0.87 (0.63, 1.20)

0.39

 

All years

  

0.84 (0.62, 1.14)

0.27

 

0.86 (0.63, 1.16)

0.32

 

Rhino-conjunctivitis symptoms with sensitization

3

12/331 (3.63%)

20/304 (6.58%)

0.55 (0.27, 1.11)

0.09

0.16

0.55 (0.28, 1.11)

0.09

0.16

6

34/304 (11.18%)

33/281 (11.74%)

0.95 (0.61, 1.49)

0.83

 

0.96 (0.61, 1.51)

0.87

 

All years

  

0.81 (0.54, 1.21)

0.30

 

0.81 (0.55, 1.21)

0.31

 

Wheeze symptoms with sensitization

1

16/357 (4.48%)

29/329 (8.81%)

0.51 (0.28, 0.92)

0.03

0.13

0.52 (0.29, 0.94)

0.03

0.13

3

36/317 (11.36%)

35/295 (11.86%)

0.96 (0.62, 1.48)

0.84

 

0.96 (0.63, 1.49)

0.87

 

6

38/290 (13.10%)

38/276 (13.77%)

0.95 (0.63, 1.45)

0.82

 

0.99 (0.65, 1.51)

0.97

 

All years

  

0.83 (0.60, 1.15)

0.26

 

0.85 (0.62, 1.17)

0.33

 

Eczema symptoms with sensitization

1

15/363 (4.13%)

22/330 (6.67%)

0.62 (0.33, 1.17)

0.14

0.68

0.63 (0.34, 1.18)

0.15

0.64

3

34/324 (10.49%)

41/301 (13.62%)

0.77 (0.50, 1.18)

0.23

 

0.78 (0.51, 1.19)

0.25

 

6

24/303 (7.92%)

26/277 (9.39%)

0.84 (0.50, 1.43)

0.53

 

0.88 (0.52, 1.50)

0.65

 

All years

  

0.76 (0.52, 1.11)

0.15

 

0.77 (0.53, 1.13)

0.19

 
  1. For ω-3 LCPUFA and control groups, data are number of subjects (percentage)
  2. Rhinitis & Rhino-conjunctivitis symptoms not assessed at 1 year
  3. Abbreviations: CI confidence interval, ω-3 LCPUFA long chain polyunsaturated fatty acid, RR relative risk
  4. a bAdjusted for enrolling centre, parity, child sex and maternal history of allergic disease